文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

再生障碍性贫血与阵发性睡眠性血红蛋白尿症中克隆演化的临床与分子决定因素

Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.
PubMed 文献 · J Clin Oncol · 2022-09-02

该多中心回顾性队列纳入1008例再生障碍性贫血(AA)与阵发性睡眠性血红蛋白尿症(PNH)患者,中位随访8.6年,评估克隆演化的临床与分子决定因素。非移植患者10年继发性髓系肿瘤(sMN)累积发生率为11.6%,sMN患者5年总生存率达40%,高危形态学、核型及ASXL1、SETBP1、RUNX1、RAS通路基因突变最常见。

要点

  • 非移植AA/PNH患者10年sMN累积发生率为11.6%,移植患者未见克隆并发症。
  • 重型AA中发病年龄较大和免疫抑制治疗无反应与sMN风险升高独立相关。
  • PIGA及BCOR/L1突变携带者sMN进展风险较低,髓系驱动突变者风险较高。

核心结论

  • AA患者sMN风险与疾病严重程度、治疗无反应及患者年龄相关。
  • sMN呈现高危形态学、核型和分子特征。
  • 获得性体细胞突变图谱复杂且尚未完全理解,在医疗管理中应谨慎考虑。

研究设计与样本

  • 多中心、回顾性队列研究,纳入1008例AA和PNH患者,中位随访8.6年。
  • 评估克隆演化的临床与分子决定因素。

主要发现

  • 初治即移植患者(n=117)未发生克隆并发症(sMN或继发性PNH)。
  • 非移植病例10年sMN累积发生率为11.6%。
  • 重型AA中,发病年龄较大和免疫抑制治疗无反应与sMN风险升高独立相关;非重型病例中未治疗患者风险最高。
  • 从AA至sMN的中位间隔时间为4.5年,94例发生sMN。
  • sMN患者5年总生存率达40%,与sMN发病时骨髓原始细胞独立相关。

局限性

  • 获得性体细胞突变图谱复杂且尚未完全理解,在医疗管理中应谨慎考虑(原文结论)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions. PATIENTS AND METHODS: We studied a multicenter, retrospective cohort of 1,008 patients (median follow-up 8.6 years) with AA and PNH to assess clinical and molecular determinants of clonal evolution. RESULTS: Although none of the patients transplanted upfront (n = 117) developed clonal complications (either sMN or secondary PNH), the 10-year cumulative incidence of sMN in nontransplanted cases was 11.6%. In severe AA, older age at presentation and lack of response to immunosuppressive therapy were independently associated with increased risk of sMN, whereas untreated patients had the highest risk among nonsevere cases. The elapsed time from AA to sMN was 4.5 years. sMN developed in 94 patients. The 5-year overall survival reached 40% and was independently associated with bone marrow blasts at sMN onset. Myelodysplastic syndrome with high-risk phenotypes, del7/7q, and ASXL1, SETBP1, RUNX1, and RAS pathway gene mutations were the most frequent characteristics. Cross-sectional studies of clonal dynamics from baseline to evolution revealed that PIGA/human leukocyte antigen lesions decreased over time, being replaced by clones with myeloid hits. PIGA and BCOR/L1 mutation carriers had a lower risk of sMN progression, whereas myeloid driver lesions marked the group with a higher risk. CONCLUSION: The risk of sMN in AA is associated with disease severity, lack of response to treatment, and patients' age. sMNs display high-risk morphological, karyotypic, and molecular features. The landscape of acquired somatic mutations is complex and incompletely understood and should be considered with caution in medical management.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gurnari C, Pagliuca S, Prata PH, et al. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. J Clin Oncol. 2022. PMID: 36054881. doi:10.1200/JCO.22.00710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。